摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基己酰氯 | 41693-47-4

中文名称
2-甲基己酰氯
中文别名
——
英文名称
2-methylhexanoyl chloride
英文别名
——
2-甲基己酰氯化学式
CAS
41693-47-4
化学式
C7H13ClO
mdl
——
分子量
148.633
InChiKey
WKEBLSOTVYFYKY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    163℃
  • 密度:
    0.957
  • 闪点:
    55°(131°F)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 危险等级:
    8
  • 海关编码:
    2915900090

SDS

SDS:de64877327047c03177503d967a0480d
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Studies on hypolipidemic agents. II Synthesis of 1-arenesulfonyloxy-2-alkanone derivatives as potent esterase inhibitors and hypolipidemic agents.
    作者:KAZUO OGAWA、TADAFUMI TERADA、YOSHIYUKI MURANAKA、TOSHIHIRO HAMAKAWA、SADAO HASHIMOTO、SETSURO FUJII
    DOI:10.1248/cpb.34.3252
    日期:——
    Many 2-oxoalkyl arenesulfonate derivatives having straight or branched alkyl chains of different lengths, 2-oxoalkyl bis-arenesulfonate derivatives, and alkyl arenesulfonate derivatives having a ketal moiety at the 2-position on the alkyl chain were synthesized, and their esterase-inhibitory activities, as well as hypolipidemic activities, were evaluated.Among these compounds, 1-(2, 4, 6-trimethylbenzenesulfonyloxy)-2-dodecanone (III-1u), and 1-(2, 3, 4, 6-tetramethylbenzenesulfonyloxy)-2-hexanone (III-1w), -2-octanone (III-1x) and -2-decanone (III-1y) exhibited potent esterase-inhibitory activities (IC50=3×10-10, 2×10-10, 2×10<-10> and 3×<-11>M, respectively). However, the sulfonate (XV) having a ketal moiety on the alkyl chain and the bis-sulfonate (XVI) exhibited low inhibitory activities toward esterase in comparison with III and XII. Most of the compounds III and some of the compounds XII exhibited potent hypolipidemic activities corresponding to more than 50% lipid-lowering effect (plasma triglyceride and cholesterol ester) in vivo. The structure-activity relatioinships of these compounds are discussed.
    合成了许多具有直链或支链不同长度烷基链的2-氧代烷基芳磺酸盐衍生物、2-氧代烷基双芳磺酸盐衍生物以及在烷基链的2-位具有缩酮部分的烷基芳磺酸盐衍生物,并评估了它们的酯酶抑制活性及降血脂活性。在这些化合物中,1-(2,4,6-三甲基苯磺酰氧基)-2-十二烷酮(III-1u)、1-(2,3,4,6-四甲基苯磺酰氧基)-2-己烷酮(III-1w)、-2-辛烷酮(III-1x)和-2-癸烷酮(III-1y)表现出强效的酯酶抑制活性(IC50分别为3×10-10、2×10-10、2×10-10和3×10-11M)。然而,相对于III和XII,具有烷基链上缩酮部分的磺酸盐(XV)和双磺酸盐(XVI)对酯酶的抑制活性较低。大多数化合物III和部分化合物XII表现出强效的降血脂活性,对应于体内超过50%的脂质降低效果(血浆甘油三酯和胆固醇酯)。讨论了这些化合物的构效关系。
  • Phenylglycine Methyl Ester, a Useful Tool for Absolute Configuration Determination of Various Chiral Carboxylic Acids
    作者:Tetsuya Yabuuchi、Takenori Kusumi
    DOI:10.1021/jo991218a
    日期:2000.1.1
    A new chiral anisotropic reagent, phenylglycine methyl ester (PGME), developed for the elucidation of the absolute configuration of chiral alpha,alpha-disubstituted acetic acids, has turned out to be applicable to other substituted carboxylic acids, such as chiral alpha-hydroxy-, alpha-alkoxy-, and alpha-acyloxy-alpha, alpha-disubstituted acetic acids, as well as to chiral beta, beta-disubstituted
    为了阐明手性α,α-二取代乙酸的绝对构型而开发的一种新的手性各向异性试剂苯甘氨酸甲酯(PGME)已证明可用于其他取代的羧酸,例如手性α-羟基- ,α-烷氧基-和α-酰氧基-α,α-二取代的乙酸,以及手性β,β-二取代的丙酸。由于羧基部分可从其他官能团转化而来,例如烯烃的臭氧分解和二醇的氧化裂解,因此,本发现可将PGME方法的用途扩展到各种类型有机化合物的绝对构型测定,甚至那些最初缺乏氧气功能。描述了化学反应和PGME方法结合的几个例子。
  • Ferric(III) Chloride Catalyzed Halogenation Reaction of Alcohols and Carboxylic Acids Using α,α-Dichlorodiphenylmethane
    作者:Chang-Hee Lee、Soo-Min Lee、Byul-Hana Min、Dong-Su Kim、Chul-Ho Jun
    DOI:10.1021/acs.orglett.8b00831
    日期:2018.4.20
    conversions of various alcohols and carboxylic acids to their corresponding alkyl and acyl chlorides in high yields under mild conditions. Particulary interesting is the observation that the respective alkyl bromides and iodides can be generated from alcohols when either LiBr or LiI are present in the reaction mixtures.
    开发了一种以α,α-二氯二苯甲烷为氯化剂,FeCl 3为催化剂的醇和羧酸氯化新方法。该方法能够在温和条件下高产率地将各种醇和羧酸转化为它们相应的烷基和酰氯。特别有趣的是观察到,当反应混合物中存在LiBr或LiI时,相应的烷基溴化物和碘化物可以由醇生成。
  • [EN] METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES<br/>[FR] MÉTHODES DE MODULATION DE L'ACTIVATION DES LEUCOCYTES ET DE LA CLAIRANCE DES THROMBOCYTES AVEC DES INHIBITEURS D'ISOENZYMES DE NEURAMINIDASE SPÉCIFIQUES
    申请人:PCHEJETSKI ALEXEY
    公开号:WO2020107124A1
    公开(公告)日:2020-06-04
    The present invention provides a method of modulating leukocytes activation (e.g., adhesion and/or transmigration and/or cytokine response) and a method of modulating thrombocyte clearance comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3) or neuraminidase 4 (neu4); or a bispecific inhibitor of neu1, neu3 or neu4 of formula (I): (I) Also provided are pharmaceutical compositions comprising the inhibitor compound of formula (1), and uses thereof for modulating leukocytes activation or modulating thrombocyte clearance.
    本发明提供了一种调节白细胞活化(例如,粘附和/或跨膜迁移和/或细胞因子反应)的方法,以及一种调节血小板清除的方法,包括向需要的受试者施用神经氨酸酶1(neu1)的特异性抑制剂;神经氨酸酶3(neu3)或神经氨酸酶4(neu4);或式(I)的神经氨酸酶1、神经氨酸酶3或神经氨酸酶4的双特异性抑制剂:(I)。还提供了包括式(1)的抑制剂化合物的药物组合物,以及用于调节白细胞活化或调节血小板清除的用途。
  • [EN] METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE<br/>[FR] MÉTHODES DE PRÉVENTION OU DE TRAITEMENT DE L'ATHÉROSCLÉROSE AVEC DES INHIBITEURS D'ISOENZYMES SPÉCIFIQUES DE LA NEURAMINIDASE HUMAINE
    申请人:UNIV ALBERTA
    公开号:WO2018213933A1
    公开(公告)日:2018-11-29
    The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bispecific inhibitor of neu1 or neu3 of formula I; (I) and a compound of formula I.
    本发明提供了一种预防或治疗动脉粥样硬化或其症状的方法,包括向需要的受试者施用神经氨酸酶1(neu1)的特异性抑制剂;神经氨酸酶3(neu3);或式I的neu1或neu3的双特异性抑制剂;(I)和式I的化合物。
查看更多